Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage

Trial Profile

Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Docetaxel; Estramustine; Hydrocortisone; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PROSTATA
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Nov 2010 Planned end date changed from 1 Jan 2010 to 1 Jul 2009 as reported by ClinicalTrials.gov.
    • 29 Nov 2010 Actual patient number is 54 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top